Long Non-coding RNA DLEU2L Targets MiR-210-3p to Suppress Gemcitabine Resistance in Pancreatic Cancer Cells Via BRCA2 Regulation

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2021 May 10

PMID 33968986

Citations 9

Authors

Fei Xu

Heshui Wu

Jiongxin Xiong

Tao Peng

Affiliations

Soon will be listed here.

Abstract

Gemcitabine (GEM) resistance remains a challenging clinical issue to overcome in chemotherapy against pancreatic cancer. We previously demonstrated that miR-210 derived from pancreatic cancer stem cells enhanced the GEM-resistant properties of pancreatic cancer cells, thus identifying miR-210 as an oncogenic miRNA. Herein, we report the existence of an upstream effector that acts as a competing endogenous RNA (ceRNA) to miR-210. Bioinformatic screening was performed to identify lncRNAs with a binding relationship to miR-210. Overexpression and interference vectors were constructed to demonstrate the effect of ceRNA activity in pancreatic cell behavior, both and . DLEU2L (deleted in lymphocytic leukemia 2-like), which is expressed at low levels in pancreatic cancer tissues, was shown to exhibit a binding relationship with miR-210-3p. Overexpression of DLEU2L and silencing of miR-210-3p suppressed the proliferation, migration, and invasion of pancreatic cancer cells while promoting apoptosis. These effects occurred via the inhibition of the Warburg effect (aerobic glycolysis) and AKT/mTOR signaling. In addition, we showed that BRCA2 is a target gene of miR-210-3p, and the downregulation of miR-210-3p by DLEU2L effectively induced an upregulation of BRCA2 via the ceRNA mechanism. , DLEU2L overexpression and miR-210-3p interference suppressed pancreatic tumor progression, consistent with the results of studies. The findings of our study establish DLEU2L as a ceRNA to miR-210-3p and reveal the critical role of the DLEU2L/miR-210-3p crosstalk in targeting GEM resistance.

Citing Articles

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.

PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.

Constructing methylation-driven ceRNA networks unveil tumor heterogeneity and predict patient prognosis.

Li X, Peng C, Liu H, Dong M, Li S, Liang W Hum Mol Genet. 2024; 34(3):251-264.

PMID: 39603659 PMC: 11792255. DOI: 10.1093/hmg/ddae176.

Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.

Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J Acta Pharm Sin B. 2024; 14(3):953-1008.

PMID: 38487001 PMC: 10935242. DOI: 10.1016/j.apsb.2023.12.003.

Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer.

Lian M, Mortoglou M, Uysal-Onganer P Curr Issues Mol Biol. 2023; 45(12):9778-9792.

PMID: 38132457 PMC: 10742176. DOI: 10.3390/cimb45120611.

Role of the long non-coding RNAs in regulation of Gemcitabine response in tumor cells.

Maharati A, Samsami Y, Latifi H, Tolue Ghasaban F, Moghbeli M Cancer Cell Int. 2023; 23(1):168.

PMID: 37580768 PMC: 10426205. DOI: 10.1186/s12935-023-03004-7.

References

Liu Y, West S . Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res. 2002; 4(1):9-13. PMC: 138716. DOI: 10.1186/bcr417. View

Yang Z, Zhao N, Cui J, Wu H, Xiong J, Peng T . Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr). 2019; 43(1):123-136. DOI: 10.1007/s13402-019-00476-6. View

Mertens D, Wolf S, Bullinger L, Ohl S, Schaffner C, Dohner H . BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31, BCMSUN-like. Int J Cancer. 2000; 88(5):692-7. DOI: 10.1002/1097-0215(20001201)88:5<692::aid-ijc2>3.0.co;2-3. View

Wei W, Chen H, Wang Z, Ni Z, Liu H, Tong H . Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci. 2012; 8(1):1-14. PMC: 3226028. DOI: 10.7150/ijbs.8.1. View

Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G . Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma. J Biol Chem. 2015; 290(28):17495-504. PMC: 4498084. DOI: 10.1074/jbc.M115.660498. View

Foster R, Griffin S, Grooby S, Feltell R, Christopherson C, Chang M . Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS One. 2012; 7(9):e45061. PMC: 3441563. DOI: 10.1371/journal.pone.0045061. View

Zaal E, Berkers C . The Influence of Metabolism on Drug Response in Cancer. Front Oncol. 2018; 8:500. PMC: 6230982. DOI: 10.3389/fonc.2018.00500. View

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

Grosso S, Doyen J, Parks S, Bertero T, Paye A, Cardinaud B . MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013; 4:e544. PMC: 3615727. DOI: 10.1038/cddis.2013.71. View

10.

Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View

11.

Ye X, Franco A, Santos H, Nelson D, Kaufman P, Adams P . Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell. 2003; 11(2):341-51. DOI: 10.1016/s1097-2765(03)00037-6. View

12.

Naderi A, Couch F . BRCA2 and pancreatic cancer. Int J Gastrointest Cancer. 2003; 31(1-3):99-106. DOI: 10.1385/IJGC:31:1-3:99. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Liu W, Jiang D, Gong F, Huang Y, Luo Y, Rong Y . miR-210-5p promotes epithelial-mesenchymal transition by inhibiting PIK3R5 thereby activating oncogenic autophagy in osteosarcoma cells. Cell Death Dis. 2020; 11(2):93. PMC: 7002725. DOI: 10.1038/s41419-020-2270-1. View

15.

Liberti M, Locasale J . The Warburg Effect: How Does it Benefit Cancer Cells?. Trends Biochem Sci. 2016; 41(3):211-218. PMC: 4783224. DOI: 10.1016/j.tibs.2015.12.001. View

16.

Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P . Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019; 19(1):618. PMC: 6591840. DOI: 10.1186/s12885-019-5824-9. View

17.

Grasso C, Jansen G, Giovannetti E . Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017; 114:139-152. DOI: 10.1016/j.critrevonc.2017.03.026. View

18.

Jones R, Kotsantis P, Stewart G, Groth P, Petermann E . BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine. Mol Cancer Ther. 2014; 13(10):2412-21. PMC: 4185294. DOI: 10.1158/1535-7163.MCT-13-0862. View

19.

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

20.

Xiong G, Liu C, Yang G, Feng M, Xu J, Zhao F . Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol. 2019; 12(1):97. PMC: 6739963. DOI: 10.1186/s13045-019-0777-7. View